Across TCGA pan-cancer cohorts, CTR9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTR9 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CTR9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CTR9 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CTR9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.848	0.554	.017	25	view →
HNSC	DFS	Median	All	0.698	1.000	.020	10	view →
LUAD	DFS	Quartile	III,IV	0.876	0.281	.004	6	view →
PDAC	OS	Median	IV	0.395	0.937	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CTR9 tumor-vs-normal RNA expression · all CTR9 data types